Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 8,349 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Toxicity Clear all
Terminated Phase 2 Interventional Results available

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

NCT01779050
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 28, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

NCT00343291
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cetuximab, Bevacizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
43
States / cities
Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 28, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

Electrical Activation of The Diaphragm for Ventilatory Assist

NCT00010374
View directory record Official record
Conditions
Spinal Cord Injury, Quadriplegia
Interventions
NeuRx DPS
Device
Lead sponsor
Synapse Biomedical
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
4
States / cities
Englewood, Colorado • Atlanta, Georgia • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 28, 2026, 1:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

NCT03471260
View directory record Official record
Conditions
Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Ivosidenib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Cleveland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

NCT00101179
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Leukemia, Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Azacitidine, Entinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 28, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

NCT05898646
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bone Marrow Aspiration, Daratumumab, Echocardiography Test, Questionnaire Administration, X-Ray Imaging, Biospecimen Collection
Procedure · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Terminated Phase 1Phase 2 Interventional

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer

NCT02575391
View directory record Official record
Conditions
Esophagitis
Interventions
Whole Food Intervention
Dietary Supplement
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 28, 2026, 1:14 AM EDT
Recruiting Not applicable Interventional

Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

NCT07662824
View directory record Official record
Conditions
Cervical Carcinoma, Endometrial Carcinoma, Overactive Bladder, Voiding Disorders
Interventions
Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation, Questionnaire Administration, Referral
Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

NCT07140679
View directory record Official record
Conditions
Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Questionnaire Administration, Toripalimab
Procedure · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors

NCT00503724
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
enzastaurin hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 28, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

NCT05176223
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional Results available

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

NCT00866723
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Serous Cancer, Fallopian Tube Cancer
Interventions
bevacizumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 28, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

NCT00047879
View directory record Official record
Conditions
Glioma
Interventions
PEG-interferon alfa-2b, Thalidomide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Oct 28, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Ramucirumab in Ovarian Cancer

NCT00721162
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Ramucirumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
11
States / cities
Hollywood, Florida • Orlando, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 28, 2026, 1:14 AM EDT
Terminated Phase 1 Interventional Results available

Thrombolysis in Pediatric Stroke (TIPS)

NCT01591096
View directory record Official record
Conditions
Stroke
Interventions
Tissue plasminogen activator (Activase®)
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 28, 2026, 1:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320
View directory record Official record
Conditions
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
432
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of N-acetylcysteine in Patients With COVID-19 Infection

NCT04374461
View directory record Official record
Conditions
Covid-19
Interventions
N-acetylcysteine, Peripheral Blood
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Not listed Phase 1Phase 2 Interventional

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

NCT03168061
View directory record Official record
Conditions
Solid Tumor, Soft Tissue Sarcoma, Metastatic Sarcoma, Sarcoma
Interventions
NC 6300
Drug
Lead sponsor
NanoCarrier Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Duarte, California • Santa Monica, California • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 28, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

NCT06630091
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Active, not recruiting No phase listed Observational

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

NCT04384770
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
CT-guided Stereotactic Body Radiation Therapy, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

NCT00735917
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
saracatinib, pharmacogenomic studies, pharmacological study, positron emission tomography, fludeoxyglucose F 18, laboratory biomarker analysis
Drug · Other · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 28, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

NCT06572618
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib, Positron Emission Tomography and Computed Tomography Scan, Rituximab
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 28, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

NCT02963090
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Topotecan, Pembrolizumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 28, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional Results available

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

NCT05581589
View directory record Official record
Conditions
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 28, 2026, 1:14 AM EDT